Gout is one of the most common inflammatory joint diseases worldwide, driven by chronically elevated levels of urate in the blood. When urate crystallizes in joints and soft tissues, it triggers excruciating attacks of arthritis and, over time, can produce tophi, the disfiguring deposits of urate crystals that characterize advanced disease. Most patients are managed with oral medications such as allopurinol or febuxostat, which reduce urate production, or uricosuric agents that increase its excretion through the kidneys. But a substantial minority of patients cannot reach target urate levels with these drugs, cannot tolerate them, or carry contraindications such as severe kidney impairment. For these individuals, guidelines in China, Europe, and elsewhere recognize an alternative approach: replacing the enzyme that humans lack.

Humans, unlike most other mammals, do not possess functional uricase, the enzyme that converts uric acid into the far more soluble compound allantoin, which is readily excreted by the kidneys. This evolutionary loss of uricase is thought to have been advantageous in our primate ancestors, possibly because uric acid acts as an antioxidant and may have helped maintain blood pressure on ancient low-salt diets. The trade-off is that humans are uniquely vulnerable to hyperuricemia. Recombinant uricase therapy restores the missing enzymatic activity pharmacologically. Rasburicase, a non-PEGylated uricase, is already used to prevent tumor lysis syndrome in oncology, while pegloticase, a PEGylated mammalian uricase, is approved for chronic refractory gout. PEGylation, the attachment of polyethylene glycol chains to a protein, extends the drug’s half-life and shields it from rapid immune clearance, but it also introduces its own immunological complications, since many people carry pre-existing antibodies against polyethylene glycol itself.

HZBio1, developed by Hangzhou Grand Biologic Pharmaceutical, is a PEGylated recombinant uricase produced in Escherichia coli. Each active enzyme molecule is a homotetramer, a four-subunit assembly in which every monomer consists of 298 amino acids. Lysine residues on the surface of the tetramer serve as convenient attachment points for polyethylene glycol modification, allowing the drug to be manufactured with a consistent architecture. The design goal is familiar to anyone following the biologics field: retain the catalytic power of the bacterial enzyme while disguising it long enough to circulate and work, and ideally with less immunogenicity than existing PEGylated uricases.

To test that concept, investigators at Peking Union Medical College Hospital in Beijing enrolled 40 healthy volunteers aged 18 to 45 years between March 2021 and January 2022. Thirty participants were randomly assigned to five dose-escalation cohorts of six subjects each, while ten received placebo. Every subject received a single intramuscular injection of either HZBio1, at doses ranging from 0.96 to 12 milligrams, or placebo. The trial was registered with ClinicalTrials.gov under identifier NCT04765995 and approved by the hospital’s ethics committee for drug clinical trials, and all participants provided written informed consent. The study followed each subject for 35 days after dosing, tracking safety, drug concentrations in plasma, uric acid dynamics, and antibody responses.

The safety picture was reassuring, if not entirely free of signals. Treatment-emergent adverse events occurred in 76.7 percent of HZBio1 recipients compared with 60.0 percent of placebo recipients, a gap that reflects the background noise of minor complaints common in any phase 1 population. Drug-related adverse events were reported in 73.3 percent of the active group versus 60.0 percent on placebo. Critically, every adverse event recorded during the follow-up period was grade 1 or grade 2 in severity, meaning mild to moderate, and the vast majority were described as mild and self-limiting. No severe events, dose-limiting toxicities, or safety signals requiring discontinuation emerged across the dose range explored.

The pharmacokinetic data revealed an intriguing property. Across the 3- to 12-milligram range, systemic exposure to HZBio1 increased in a greater than dose-proportional manner, meaning that doubling the dose more than doubled the drug’s presence in the bloodstream. Such super-proportional exposure can occur when a drug’s absorption or clearance pathways become saturated, and it has practical implications for dosing, since small increments in dose may produce disproportionately large changes in exposure. For a first-in-human program, characterizing this nonlinearity early is exactly what dose-escalation studies are designed to accomplish, and it will inform how future trials select and space doses.

The pharmacodynamic results were the trial’s headline attraction. A single injection of HZBio1 sent plasma uric acid concentrations falling, with levels reaching their nadir between 144 and 192 hours after dosing, roughly six to eight days. The reduction was most pronounced in the 9- and 12-milligram cohorts, and among subjects receiving 6 to 12 milligrams, participants achieved at least a 50 percent reduction in plasma urate over the 35-day observation period. A urate-lowering effect of that magnitude and duration, from a single intramuscular dose, is notable because it suggests the PEGylated enzyme remains active in circulation for an extended period, potentially allowing an infrequent dosing schedule that would be attractive for a chronic disease like gout.

Immunogenicity, the perennial concern with PEGylated proteins, was monitored with equal care. HZBio1 administration elicited low-titer antibodies against polyethylene glycol, of both the immunoglobulin G and immunoglobulin M classes. By contrast, antibodies directed against the drug protein itself were rarely detected, and no subject developed neutralizing antibodies, the kind that would inactivate the enzyme and potentially blunt or abolish its therapeutic effect. The distinction matters because neutralizing antidrug antibodies are the principal reason some patients lose response to pegloticase, and pre-existing or induced anti-PEG antibodies have been linked to infusion reactions with other PEGylated medicines. Whether the low-titer anti-PEG response observed here remains clinically silent with repeated dosing is a question only longer studies can answer.

The authors conclude that HZBio1 at doses of 3 to 12 milligrams was well tolerated in healthy subjects, showed an acceptable pharmacokinetic profile, and produced a promising urate-lowering effect. The trial was funded by Hangzhou Grand Biologic Pharmaceutical, with the funder reporting no role in the design, conduct, analysis, or reporting of the research; two authors are company employees and one is employed by Grand Life Sciences Group, while the academic investigators disclosed no conflicts of interest. As with any phase 1a study, the caveats are substantial: only 40 subjects were involved, all were young and healthy Chinese adults rather than patients with gout, and each received just one dose. The super-proportional exposure seen at higher doses will need careful management in patient trials, and the durability of the immune response under repeated administration remains untested. Nevertheless, the combination of mild adverse events, sustained urate suppression, and an apparently favorable antibody profile gives HZBio1 a credible foundation for advancing into phase 1b and phase 2 studies in the hyperuricemic and gout populations who most need a new enzymatic option.

Subject of Research: First-in-human phase 1a evaluation of the PEGylated recombinant uricase HZBio1 for hyperuricemia and gout

Article Title: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study

Article References: Liu, H., Zheng, X., Yang, C., Tian, W., Wan, R., Wang, Y., Yu, Y., Wang, Q., & Wang, H. (2026). Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03792-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03792-0

Keywords: HZBio1, PEGylated uricase, gout, hyperuricemia, phase 1a trial, pharmacokinetics, pharmacodynamics, immunogenicity, anti-PEG antibodies, urate-lowering therapy, biologics, first-in-human study

The study, led by Ju Hee Kim and Jungbin Song with colleagues at CHA University, Kyung Hee University, and Korea University Guro Hospital, examined three herbal formulations: Bojungikgitang, Ijintang, and Cheongsanggyeontongtang. All three have long histories of symptomatic use in East Asian traditional medicine for cardiovascular and cerebrovascular conditions—precisely the patient populations most likely to be taking anticoagulants. The research team designed a fixed-sequence, two-period clinical trial in which healthy volunteers received a single 60-milligram dose of edoxaban alone, and then received the same dose after repeated dosing with one of the three herbal formulations. The design allowed each participant to serve in part as their own control, isolating the effect of the herbal co-administration from natural interindividual variability in drug handling.

Edoxaban is a direct factor Xa inhibitor, a member of the direct oral anticoagulant family that has largely displaced warfarin in many markets because it requires no routine monitoring and has fewer dietary interactions. Its disposition in the body, however, depends heavily on the efflux transporter P-glycoprotein and, to a lesser extent, on cytochrome P450 3A4 (CYP3A4) metabolism, which produces an active metabolite known as M4. This pharmacological profile makes edoxaban particularly vulnerable to interactions with drugs—and potentially herbal phytochemicals—that inhibit or induce P-glycoprotein or CYP3A4. Strong P-glycoprotein inhibitors such as quinidine and cyclosporine are already known to raise edoxaban levels, while inducers such as rifampin can slash them, and the edoxaban label reflects those established interactions.

To measure what the herbal formulations did to edoxaban, the researchers quantified plasma concentrations of both the parent drug and its active M4 metabolite using liquid chromatography coupled with tandem mass spectrometry, a gold-standard bioanalytical technique aligned with international ICH M10 validation guidance. Pharmacokinetic parameters—the area under the concentration-time curve, peak concentrations, and clearance measures—were compared between treatment periods using linear mixed-effects models, a statistical framework well suited to repeated-measures crossover designs. In parallel, the team assessed pharmacodynamic effects using prothrombin time and activated partial thromboplastin time, the two coagulation assays most commonly used to gauge anticoagulant intensity at the bedside. Finally, in laboratory experiments, the formulations were tested for their capacity to inhibit CYP3A4 activity in vitro.

The pharmacokinetic results were striking in their divergence. Bojungikgitang approximately doubled systemic exposure to edoxaban, effectively reproducing the magnitude of interaction seen with known strong P-glycoprotein inhibitors. At the other extreme, Cheongsanggyeontongtang reduced edoxaban exposure by roughly 40 percent—a reduction in the range that regulators associate with inducers of the drug’s clearance pathways and one that could, in theory, erode the anticoagulant’s protective effect against stroke. Ijintang, by contrast, exerted only minimal effects on the drug’s pharmacokinetic profile. The active metabolite M4 followed the same directional pattern as the parent compound in each case, indicating that the herbal formulations were shifting edoxaban’s overall systemic disposition rather than selectively rerouting its metabolism.

Perhaps the most provocative—and most cautionary—finding came from the pharmacodynamic measurements. Despite the substantial pharmacokinetic shifts, the researchers detected no significant changes in prothrombin time or activated partial thromboplastin time in any of the herbal co-administration groups. In other words, a patient’s exposure to edoxaban could double, or fall by 40 percent, while the standard laboratory coagulation tests remained essentially silent. This dissociation matters because clinicians sometimes lean on coagulation assays when concerns arise about anticoagulant intensity, and the results suggest those assays are poor sentinels for herb-driven changes in edoxaban levels. The therapeutic window of a drug, not the laboratory value alone, ultimately determines whether exposure changes translate into bleeding or thrombotic risk.

The mechanistic work offered clues about how the divergent effects arise. In vitro testing showed negligible inhibition of CYP3A4 by Bojungikgitang and Ijintang and only weak inhibition by Cheongsanggyeontongtang, indicating that direct CYP3A4 blockade is unlikely to explain the doubling of edoxaban exposure seen with Bojungikgitang. The more plausible culprit is interference with P-glycoprotein, the efflux pump that governs edoxaban’s intestinal absorption and biliary excretion. Many phytochemicals common in traditional formulas—including compounds found in ginseng, licorice, and astragalus, herbs represented in some of these formulations—have been shown in laboratory studies to modulate P-glycoprotein and CYP enzymes. The precise constituent responsible for the Bojungikgitang effect, however, remains to be pinned down, and the authors’ data do not permit attribution to a single botanical ingredient.

The clinical context amplifies the significance of the findings. Surveys of Korean medical hospital practice have documented frequent combination therapy between herbal extracts and antiplatelet or anticoagulant drugs in ischemic stroke patients, and Korean medicine clinical practice guidelines for stroke, developed under the National Institute for Korean Medicine Development, formalize herbal care pathways for the same patients who often need anticoagulation. Case reports from around the world have described increased bleeding in patients combining oral anticoagulants with herbal products ranging from saffron to Salvia miltiorrhiza, and St John’s wort has been shown to lower rivaroxaban exposure in controlled human studies. Meanwhile, cohort data have suggested that some concurrent Chinese herbal medicine use may even be associated with fewer major bleeding events, underscoring that the herb-drug interaction landscape is neither uniformly dangerous nor uniformly benign—it is formulation-specific, and largely unmapped.

That is precisely the gap this trial helps to fill. By testing three named, commercially supplied formulations under controlled conditions in healthy volunteers, and by measuring both drug levels and clotting outcomes with validated methods, the Korean team has converted a vague anxiety—herbs might interact with blood thinners—into concrete, quantifiable risk statements: Bojungikgitang approximately doubles edoxaban exposure, Cheongsanggyeontongtang cuts it by about 40 percent, Ijintang is relatively benign, and conventional coagulation tests will not warn you about any of it. The authors conclude that clinical consideration is warranted when edoxaban is combined with Bojungikgitang or Cheongsanggyeontongtang, and the magnitude of the observed changes supports that caution, situating both interactions on par with labeled drug-drug interactions of edoxaban.

Important caveats temper the translation to patient care. The study enrolled healthy volunteers, not the older, multimorbid patients with atrial fibrillation or venous thromboembolism who actually take edoxaban, and it could not assess hard clinical endpoints such as bleeding or stroke. Fixed-sequence designs and modest sample sizes, typical of exploratory interaction studies, also limit generalizability, and the duration of herbal pre-dosing may not capture longer-term induction or adaptation effects. Even so, the work delivers a clear, actionable message for prescribers, pharmacists, and practitioners of traditional medicine alike: herbal formulations are not pharmacologically inert companions to modern anticoagulants. Until larger outcome studies are done, patients taking edoxaban who also use Bojungikgitang or Cheongsanggyeontongtang deserve explicit attention, honest conversations about herbal supplement use, and a healthy skepticism toward coagulation tests that may not reveal what the body is actually doing.

Subject of Research: Herb-drug interactions between traditional Korean herbal formulations and the anticoagulant edoxaban

Article Title: Effects of Bojungikgitang, Ijintang, and Cheongsanggyeontongtang on the pharmacokinetics and pharmacodynamics of edoxaban

Article References: Kim, J. H., Song, J., Kim, M., Kim, H., Cho, H.-Y., & Chung, H. (2026). Effects of Bojungikgitang, Ijintang, and Cheongsanggyeontongtang on the pharmacokinetics and pharmacodynamics of edoxaban. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00828-z

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00828-z

Keywords: edoxaban, herb-drug interaction, Bojungikgitang, Ijintang, Cheongsanggyeontongtang, pharmacokinetics, pharmacodynamics, direct oral anticoagulants, P-glycoprotein, CYP3A4, traditional Korean medicine, clinical trial

The team, led by co-first authors Judith Verdonk and Leila-Sophie Otten under the supervision of pharmacist Rob ter Heine, focused on non-small cell lung cancer, the setting in which pembrolizumab is most commonly used. Three approved dosing regimens were compared in silico: 2 milligrams per kilogram every three weeks, a flat 200 milligrams every three weeks, and a flat 400 milligrams every six weeks. These regimens were established through modelling and simulation during drug development, but the authors argue that the pharmacodynamic surrogate underpinning them, peripheral receptor occupancy, has never been rigorously validated as a predictor of clinical benefit.

To build their model, the researchers started from a physiological pharmacokinetic framework describing how pembrolizumab moves through plasma and penetrates tumour tissue. Antibody tumour penetration is a notoriously inefficient process, governed by convective transport, diffusion and antigen-mediated binding that can slow or even reverse the movement of drug into tumour interstitium. The model accounted for these dynamics, extending earlier work on antibody tumour transport, and then added two crucial layers: receptor occupancy kinetics and the induction of interleukin-2, a cytokine whose production reflects genuine T cell activation rather than mere receptor blockade.

The interleukin-2 parameters were not invented from thin air. They were derived from ex vivo experiments in which patient T cells were exposed to pembrolizumab and their functional responses measured. This experimental grounding matters, because an earlier study by the same group had already revealed a critical gap between receptor occupancy and T cell functionality: cells whose PD-1 receptors were fully occupied by the drug did not necessarily show the downstream signalling and cytokine production that clinicians would want to see. The new study translates that laboratory observation into a quantitative, patient-scale simulation framework.

The simulations produced a striking and, for the field, uncomfortable result. All three approved regimens achieved near-complete PD-1 receptor occupancy, both in the circulation and within the tumour microenvironment. On the traditional view, this means all three doses should be pharmacodynamically equivalent, and indeed this saturation logic is precisely why regulators and developers accepted the regimens as interchangeable. Yet when the researchers looked at predicted interleukin-2 concentrations, a very different picture emerged. The cytokine levels were predicted to rise and fall throughout the dosing interval, tracking the concentration of pembrolizumab itself rather than the occupancy of its receptor.

Even more provocatively, the 400 milligram every-six-weeks regimen, the highest total dose per interval, produced the highest predicted interleukin-2 levels. If immune activation rather than receptor saturation is what drives anti-tumour efficacy, then the longest-interval regimen may not be a mere convenience option but potentially the most immunologically active of the three. The authors are careful to note that interleukin-2 is a marker, not a proven mediator of clinical response, and that more activation is not automatically better; excessive immune stimulation can contribute to toxicity. But the finding decisively breaks the assumed link between occupancy and pharmacodynamic effect.

A second important nuance concerned the tumour itself. Changes in intratumoural interleukin-2 concentrations were predicted to be considerably less pronounced than those in plasma. In other words, even if systemic immune activation fluctuates substantially between doses, the immune microenvironment inside the tumour may experience a more buffered response. This has implications for how biomarkers are interpreted: a blood sample showing robust cytokine swings may not faithfully represent what is happening at the site where the immune system meets the cancer. It also raises the possibility that intratumoural pharmacodynamics, not plasma pharmacokinetics, should be the target of future dose optimisation efforts.

The broader context makes these findings timely. Pembrolizumab is expensive, and health systems worldwide have scrutinised whether lower doses or longer intervals could deliver the same benefit at reduced cost. Pharmacokinetic simulation studies and even randomised trials of low-dose immunotherapy in head and neck cancer have suggested that less drug may suffice. Meanwhile, other lines of research have explored whether the timing of infusion within the day, circadian chronotherapy, influences survival. What has been missing from all these debates is a validated pharmacodynamic marker that actually reflects the biological effect the drugs are meant to produce. This study argues that receptor occupancy, the marker the field has relied upon, fails that test.

The authors conclude that receptor occupancy is an inadequate pharmacodynamic surrogate for pembrolizumab and, by extension, for the broader class of PD-1 inhibitors. They call for the development of robust pharmacodynamic markers and, crucially, a clearer definition of the level and pattern of immune activation required for optimal efficacy. Until such markers exist, dose selection for checkpoint inhibitors will remain guided by surrogates that may bear little relationship to the biology that matters. The study, funded by Stichting Treatmeds as part of the NVALT30/DEDICATION-1 trial programme, was approved by the ethics committee METC Oost-Nederland and conducted according to the Declaration of Helsinki. Its message is likely to resonate far beyond lung cancer: for a drug class that has transformed oncology, the question of how much drug patients really need may have been asking the wrong question all along.

Subject of Research: Translational pharmacokinetic-pharmacodynamic modelling of pembrolizumab dosing, receptor occupancy and immune activation in non-small cell lung cancer

Article Title: Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab

Article References: Verdonk, J. D. J., Otten, L.-S., Montaseri, G., van den Heuvel, M. M., Smeets, R. L., Koenen, H. J. P. M., & ter Heine, R. (2026). Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03612-w

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03612-w

Keywords: pembrolizumab, PD-1 inhibitors, receptor occupancy, cancer immunotherapy, pharmacokinetic modelling, interleukin-2, non-small cell lung cancer, dose optimisation, pharmacodynamics, immune checkpoint inhibitors, tumour penetration, drug dosing

The central concept behind the research is receptor saturation. Atezolizumab is a monoclonal antibody designed to bind PD-L1, a protein that many tumours deploy on their surfaces to suppress the immune cells that would otherwise attack them. By occupying PD-L1, atezolizumab blocks this molecular camouflage and releases the brakes on the immune system. But the drug can only work where it actually reaches the target in sufficient quantity. If a tumour expresses abundant PD-L1 but has poor blood supply, dense stromal barriers, or unfavourable pharmacokinetics, the antibody may fail to saturate the target even though the patient receives a full therapeutic dose. Conventional testing, which involves staining a biopsy sample for PD-L1 expression, captures only a snapshot of a tiny fragment of the tumour at a single moment in time and says nothing about whether the drug is engaging its target throughout the body.

PET imaging offers a fundamentally different perspective. In the approach examined by the researchers, atezolizumab is labelled with a radioactive tracer, typically the radionuclide zirconium-89, whose decay signature can be detected by the PET scanner. When the labelled antibody is injected into a patient, the scanner produces three-dimensional maps showing exactly where the drug accumulates. If a tumour lights up with signal before treatment, it indicates that PD-L1 is present and accessible to the antibody. If the signal diminishes or disappears after the patient begins therapy with unlabelled atezolizumab, it indicates that the therapeutic antibody has flooded the target sites, occupying them so thoroughly that the labelled tracer can no longer bind. This drop in tracer uptake is the imaging signature of target saturation, the pharmacodynamic state in which the drug is doing its intended molecular job at the tumour site.

The logic of this imaging paradigm rests on a simple competitive principle. Before treatment begins, when no therapeutic antibody is circulating, the radiolabelled atezolizumab analogue can bind freely to PD-L1 molecules on tumour cells, producing strong PET signal. Once a patient starts standard atezolizumab infusions, the circulating therapeutic antibody competes with the tracer for the same binding sites. As the drug concentration rises and saturates available PD-L1, tracer uptake falls. The degree of that fall provides a direct, whole-body measure of how completely the treatment is engaging its target in each tumour lesion. This is often described as an in vivo pharmacodynamic biopsy: instead of sampling one lesion surgically, clinicians can observe drug-target interactions across every detectable tumour deposit simultaneously, including metastases in locations that could never be biopsied safely.

The significance of this capability becomes clear when considering how immunotherapy is currently managed. Patients with non-small cell lung cancer, bladder cancer, and other PD-L1-positive malignancies typically receive atezolizumab or similar agents on fixed schedules, often for months, before standard imaging can reveal whether the tumours are shrinking. Response assessment by CT generally takes weeks to months to show meaningful change, because tumour shrinkage is a delayed downstream consequence of immune activation. Target saturation, by contrast, is an immediate upstream event. If imaging shows that the antibody has fully occupied PD-L1 within days of the first dose, and the tumour still fails to respond over the following months, the problem lies elsewhere: the tumour may have developed alternative immune-evasion mechanisms, the tumour microenvironment may lack infiltrating T cells, or downstream signalling may be blocked. Distinguishing pharmacokinetic failure, where the drug never reached the target, from biological resistance, where the drug engaged the target but the cancer resisted anyway, is exactly the information that saturation imaging is designed to provide.

Past work in this field has demonstrated the technical feasibility of the approach. Radiolabelled versions of atezolizumab and the related antibody pembrolizumab have been used in early-phase clinical trials, showing that PD-L1-specific PET signal can be detected in human tumours, that uptake varies widely between patients, and that heterogeneity exists even among different metastatic lesions within the same individual. These studies revealed something that biopsies had long obscured: a patient whose primary tumour shows strong PD-L1 staining may harbour liver metastases with negligible target expression, and those lesions may behave very differently under treatment. Quantitative measures derived from PET scans, such as standardised uptake values, have been correlated with clinical outcomes in preliminary analyses, hinting that baseline tracer uptake and early changes during therapy could serve as predictive biomarkers in their own right.

Dosing is another area where saturation imaging carries substantial implications. Current atezolizumab regimens were established through trials that sought doses safely exceeding the levels needed for receptor occupancy, but those occupancy estimates were largely derived from circulating drug levels and receptor occupancy measurements on peripheral blood cells, not from direct measurements inside tumours. Tumour penetration is governed by different physics: antibody extravasation through leaky but uneven vasculature, diffusion through the extracellular matrix, binding-site barriers created by dense target expression near blood vessels, and clearance rates that vary with tumour type and location. PET saturation imaging brings these hidden variables into view. A tumour that retains strong tracer uptake even after multiple treatment doses is telling clinicians that the target remains unsaturated, suggesting that dose escalation, altered scheduling, or combination strategies that improve drug delivery might be worth considering for that specific patient.

The study published in the British Journal of Cancer contributes to this evolving evidence base by evaluating PD-L1 PET/CT specifically as a tool to assess tumour saturation during atezolizumab treatment. The broader research programme of which it forms a part reflects a decisive shift in oncology drug development: away from one-size-fits-all dosing and toward imaging-verified pharmacodynamics. Regulatory science has begun to take note. Methods that demonstrate target engagement early in treatment could accelerate clinical trials by providing early surrogate indicators, reducing the sample sizes and follow-up durations needed to establish whether a drug regimen is mechanistically active. They could also support adaptive treatment strategies in routine care, in which imaging results after the first one or two doses inform whether the patient should continue, switch, or intensify therapy long before tumour volume changes would be visible.

Challenges remain before such imaging can enter routine practice. Radiolabelling antibodies with zirconium-89 requires cyclotron facilities, radiochemistry expertise, and regulatory compliance that currently limits availability to specialised centres. The half-life of zirconium-89, roughly 78 hours, suits the slow pharmacokinetics of antibodies, which circulate for days to weeks before reaching peak tumour uptake, but it also means patients must return for scans several days after injection and absorb a meaningful radiation dose. Cost, reimbursement, and the need for standardised scanning protocols and uptake thresholds all stand between promising trial results and clinical adoption. Questions also persist about how best to interpret partial saturation, how tracer signal in the liver and spleen, organs with high background antibody uptake, affects quantification of abdominal lesions, and how the immune response triggered by treatment itself alters target expression over time.

Nevertheless, the trajectory of the field is unmistakable. Molecular imaging of drug-target engagement is converging with immunotherapy at a moment when the limitations of current biomarkers have become painfully evident. PD-L1 immunohistochemistry, tumour mutational burden, and gene-expression signatures each capture only a fragment of the biology that determines whether a patient responds to checkpoint blockade. Saturation imaging promises something those tools cannot: a dynamic, whole-body, patient-specific readout of whether the drug is doing, at the molecular level, what it was designed to do. If validated in larger cohorts, the approach exemplified by this line of research could move immunotherapy closer to the ideal of precision medicine, where the first weeks of treatment generate actionable information rather than a waiting period measured in months. For the many patients whose tumours do not respond to atezolizumab and its peers, that shift could mean less time on ineffective therapy, faster transitions to alternatives, and a clearer mechanistic understanding of why immunotherapy succeeds or fails in each individual.

Subject of Research: PD-L1 PET/CT molecular imaging to assess tumour target saturation during atezolizumab immunotherapy

Article Title: Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment

Article References: Hooiveld-Noeken, J. S., van de Donk, P. P., Kist de Ruijter, L., Kok, I. C., van Winkel, C. A. J., Giesen, D., Lub-de Hooge, M. N., Brouwers, A. H., Oosting, S. F., Bensch, F., Smit, L. M., Schröder, C. P., Jalving, M., Elias, S. G., Gietema, J. A., Deurloo, R. J., Williams, S. P., Ungewickell, A., de Groot, D.-J. A., & de Vries, E. G. E. (2026). Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03595-8

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03595-8

Keywords: PD-L1, PET/CT imaging, atezolizumab, immunotherapy, checkpoint inhibitors, target saturation, molecular imaging, radiotracer, tumour microenvironment, pharmacodynamics, precision oncology, British Journal of Cancer